Gervasio A. Lamas, MD of Mount Sinai Medical Center and Columbia University Medical Center presented at Brigham and Women’s Hospital Cardiovascular Grand Rounds in March 2019. His presentation was titled, “How Treating the Elephant in the Room Became a Black Swan Event: Toxic Metals and Cardiovascular Disease.”
Before and after photos presented at 2019 International Symposium on Endovascular Therapy (ISET) show the effect of chelation therapy in diabetic patients with critical limb ischemia (CLI), highlighting its potential to improve unhealed ulcers and gangrene. Presenter Gervasio A. Lamas, MD has devoted many years to investigating the therapy’s potential, most famously in the TACT trial of post-MI patients.
An e-poster and presentation at the 31st International Symposium on Endovascular Therapy (ISET) highlighted positive results from a pilot study of edetate disodium-based chelation in diabetic patients with critical limb ischaemia (CLI). The study authors noted that TACT demonstrated a reduction in cardiac events in diabetic patients receiving edetate disodium-based chelation.
Scott Doughty, MD aims to decrease the number heart attacks, strokes, and deaths for individuals through TACT2 and chelation therapy. Dr. Doughty is the startup inspiration behind U.P. Holistic Medicine, one of seven clinical sites in Michigan. Of these seven sites, U.P. Holistic Medicine currently ranks second in number of participants, just behind Henry Ford Hospital.
Chelation therapy was developed in the 1930s and was designed to remove heavy metals from the blood of severely metal-poisoned patients. In 2012, findings from the Trial to Assess Chelation Therapy (TACT) demonstrated benefits from chelation, particularly in diabetic patients with heart disease. The National Institutes of Health is supporting a second trial, TACT2, to verify the benefits of chelation therapy in diabetic patients who have had a prior heart attack.
The Trial to Assess Chelation Therapy (TACT) demonstrated a major improvement in ischemic cardiac events in diabetic patients randomized to edetate disodium-based chelation. Research findings presented at the American Heart Association’s Scientific Sessions 2018 suggest that TACT infusions in diabetic patients with critical limb ischemia are safe, increase excretion of vasculotoxic metals, may improve quality of life, and might improve clinical outcomes.
Clinician-scientist Bruce Lanphear, MD, has produced a video on the lead pandemic: “Over the last century the planet has experienced the largest mass contamination in history, a pandemic of lead poisoning. Brought on by the deception and negligence of a corporate collusion to extract immense profit from the sale of a known, harmful material, the subsequent waste has cast a toxic shadow over the earth, leaving in its wake death, disease and crime.”
There’s one possible reason so many Americans, especially those living in inner cities, have high blood pressure: lead exposure.
Researchers tested people’s bones for evidence they took in lead over the years. The heavy metal accumulates in bone and stays there for decades as people drink lead-tainted water, breathe in dust carrying lead or get it some other way. But if something causes its release — anything from simple aging to pregnancy or thyroid disease — it can raise blood pressure.
Learn about the Trial to Assess Chelation Therapy 2 (TACT2) in this free presentation from the study chairman, Dr. Gervasio Lamas. Audio included.
Chelation therapy has long been scorned by many in the medical community. But after a major study suggested it was somewhat effective for heart disease, the alternative health treatment is once again going under the microscope. A second study called TACT 2 (Trial to Assess Chelation Therapy) will assess chelation’s heart-health benefits for patients with diabetes.